Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Key Inclusion Criteria:

Availability of tumor tissue (archived and fresh tumor biopsy, if medically feasible)
Select advanced or metastatic solid tumor that is likely to express CLDN18.2 such as gastric/GEJ, pancreatic and esophageal cancer
≥ 18 years of age
ECOG performance status (PS) 0 or 1 at Screening
Progressed on or after standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy
Have at least one measurable extra-cranial lesion as defined by RECIST v1.1
Adequate organ function
Life expectancy > 12 weeks
Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent
Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following study completion

Key Exclusion Criteria:

Pregnant or breastfeeding
Symptomatic or untreated brain metastases
Have previously received CLDN18.2 antibody drug conjugates (ADCs) or any ADC containing an auristatin payload (prior monoclonal antibody against CLDN18.2 may be eligible)
Have peripheral neuropathy Grade ≥2
Have history of non-infectious pneumonitis/interstitial lung disease
Have diagnosis of another malignancy, or history of systemic treatment for invasive cancer within last 3 years. Note: Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. Diagnosis of non-melanoma skin cancer, carcinoma in situ of the cervix or breast, or noninvasive tumor does not affect eligibility
Have active ocular surface disease at baseline (based on screening ophthalmic examination)
Have serious concurrent illness or clinically relevant active bacterial, fungal or viral infection
Have previous hypersensitivity to any known components of EO-3021 or history of severe infusion reaction or hypersensitivity (CTCAE Grade 3 or higher) with monoclonal antibody treatment
Clinically significant cardiac disease, including but not limited to symptomatic congestive heart failure, unstable angina, acute myocardial infarction within 6 months of planned first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de pointes)
Have history of allogenic hematopoietic stem cell transplantation or solid organ transplantation with ongoing systemic immunosuppressive therapy
Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the Investigator